For Calendar Q1 2021 Apple Grew iPhone Shipments 44% Year-over-Year
Apple to become the largest procurer of smartphone OLED panels this year with LG Display doubling its iPhone Display Shipments

AliveCor Files a Complaint against Apple with the ITC alleging patent infringement on three of their ECG technology patents



Late yesterday AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, announced that it had filed a complaint with the U.S. International Trade Commission (ITC), alleging Apple's infringement of three AliveCor patents. Starting in 2011, AliveCor has invested heavily in bringing advanced, AI-powered cardiological detection technology to consumer users. These investments have produced unique, market changing products including:


  • KardiaMobile, the most clinically-validated personal ECG in the world
  • KardiaMobile 6L, the first and only six-lead personal ECG
  • KardiaBand, the first FDA-cleared medical device accessory for Apple Watch
  • SmartRhythm, revolutionary artificial intelligence that continuously evaluates heart activity for signs of arrhythmias


In December 2020, AliveCor filed a federal lawsuit alleging Apple infringement of the same patents. AliveCor contends that Apple Inc. is infringing AliveCor's asserted patents through the sale of Apple watches that employ infringing functionality.


Filing in the ITC "is one step, among others, AliveCor is taking to obtain relief for Apple's intentional copying of AliveCor's patented technology—including the ability to take an ECG reading on the Apple Watch, and to perform heartrate analysis—as well as Apple's efforts to eliminate AliveCor as competition in the heartrate analysis market for the Apple Watch."


AliveCor's Filing with the ITC is seeking to bar U.S. Importation of Apple Watch.


10.0F - Apple News


The comments to this entry are closed.